You just read:

Heptares Announces Positive Outcome of Phase 1A Study with First-ever Selective Muscarinic M1 Receptor Agonist for Improving Cognition in Patients With Alzheimer's Disease

News provided by

Heptares Therapeutics

17 Jun, 2015, 07:30 BST